Heart-fatty acid binding protein in dogs with degenerative valvular disease and dilated cardiomyopathy

Lam, Christopher; Casamian‐Sorrosal, Domingo; Monteith, Gabrielle; Fonfara, Sonja

doi:10.1016/j.tvjl.2018.11.017

Cited by 4 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the true limits of normality may be lower or higher than the threshold used in this study. However, if we examine the HFABPc values of a control population ( n = 21) in a previous study, 21 they were very similar (indeed slightly higher) with an upper limit threshold at 0.80 ng/mL (0.64 ng/mL was used in our study). Therefore, the considerations and conclusions discussed in this article seem appropriate.…”

Section: Discussionmentioning

confidence: 67%

“…It is unclear why HFABP, unlike cTnI in previous studies, 6,7,10,12 was not associated with clinical results in CanL. HFABPc has been shown to be elevated in humans with myocardial infarction 16–19 and DCM 20 and in dogs with DCM 21 and MVD 21 . It is a biomarker characterised by rapid increase after myocardial injury, 16 a short half‐life and a rapid decrease after the insult when compared with cTnI 16–19 .…”

Section: Discussionmentioning

confidence: 92%

“…HFABPc was measured in EDTA plasma using a dog‐specific ELISA test (Kamiya Biomedical Company, Tukwila, WA, USA). Intra‐ and interassay coefficients of variation of the test had been previously determined using adult dog plasma samples and were 8.3% and 10.0%, respectively 21 . The range of the test was between 0.1 and 20 ng HFABP/mL.…”

Section: Methodsmentioning

confidence: 99%

“…HFABP is involved in fatty acid transport and metabolism 16,17 and is rapidly released into the systemic circulation after myocardial damage 16 . HFABP is a novel biomarker used in human patients with cardiac disease, 16–20 and it has also been investigated in dogs with acquired cardiac diseases 21 . HFABP has been shown to be elevated and an independent predictor of survival in dogs with dilated cardiomyopathy (DCM) and degenerative mitral valve disease (MVD) 21 .…”

Section: Introductionmentioning

confidence: 99%

“…21 HFABP has been shown to be elevated and an independent predictor of survival in dogs with dilated cardiomyopathy (DCM) and degenerative mitral valve disease (MVD). 21 The principal cardiac alteration in CanL is myocarditis (mostly lymphoplasmacytic), 4,5,7,8,10 which leads to a variable degree of myocardial damage 4,5,7,8,10,12 and makes HFABP a potentially adequate biomarker in CanL. An increase in left ventricular thickening and increased left ventricular mass (LVM) have been consistently reported in dogs with advanced CanL.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Evaluation of heart fatty acid‐binding protein as a biomarker for canine leishmaniosis

et al. 2023

View full text Add to dashboard Cite

Background: Myocarditis frequently occurs in canine leishmaniosis (CanL). Heart fatty acid-binding protein (HFABP) is a biomarker of myocardial damage. Methods: This study aimed to compare HFABP concentration (HFABPc) in healthy dogs and dogs at different stages of CanL and evaluate the correlation of this biomarker with several clinicopathological and echocardiographic variables. Thirty-one dogs diagnosed with CanL and 10 healthy dogs were included. Results: HFABPc was not statistically different (p > 0.05) between groups of dogs at different LeishVet stages of CanL or between groups with high versus low to intermediate serology titres. In 70% of CanL dogs, HFABPc was within the 95% confidence interval limits of the mean of healthy dogs. A moderate negative correlation with globulin (r = −0.519; p = 0.03) and haematocrit (HCT) (r = −0.538; p = 0.02) was observed. No other significant correlation (p > 0.05) was observed with any other variable. Limitations: Many statistical tests were performed, and therefore, type I error cannot be ruled out. Conclusion: HFABPc is not consistently elevated in dogs with CanL and is not associated with the severity of the disease, or most echocardiographic or clinicopathological variables studied. The correlation with globulin and HCT was not strong and not considered clinically significant. HFABPc lacks sufficient predictive capacity in dogs with CanL, discouraging further research or clinical use of this biomarker in this disease.

show abstract

Section: Discussionmentioning

confidence: 67%